{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:42:46Z","timestamp":1788316966837,"version":"build-2803163510"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100032148","name":"Biohaven Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032148","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013140","name":"Colorectal Cancer Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013140","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.yebeh.2025.110670","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T02:55:53Z","timestamp":1756954553000},"page":"110670","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Understanding lived experiences with KCNQ2 developmental and epileptic encephalopathy"],"prefix":"10.1016","volume":"172","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7389-3354","authenticated-orcid":false,"given":"Michele H.","family":"Potashman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7220-8562","authenticated-orcid":false,"given":"Katja","family":"Rudell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Abetz-Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6347-6704","authenticated-orcid":false,"given":"Naomi","family":"Suminski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7585-1989","authenticated-orcid":false,"given":"Audra","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinchen","family":"Doma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Jarodia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Ridley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7133-2921","authenticated-orcid":false,"given":"Jason","family":"Lerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Mather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad","family":"Coric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1594-9812","authenticated-orcid":false,"given":"Adam L.","family":"Numis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7285-1195","authenticated-orcid":false,"given":"Tristan T.","family":"Sands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Millichap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0298-5523","authenticated-orcid":false,"given":"Anne T.","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"L\u2019Italien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2025.110670_b0005","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/acn3.51316","article-title":"KCNQ2-DEE: developmental or epileptic encephalopathy?","volume":"8","author":"Berg","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.yebeh.2025.110670_b0010","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1093\/brain\/awz195","article-title":"Incidence and phenotypes of childhood-onset genetic epilepsies: a prospective population-based national cohort","volume":"142","author":"Symonds","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.yebeh.2025.110670_b0015","unstructured":"Weckhuysen S, George JAL. KCNQ2- and KCNQ3-Associated Epilepsy. Cambridge: Cambridge University Press; 2022."},{"key":"10.1016\/j.yebeh.2025.110670_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2023.109153","article-title":"Clinical characteristics of 80 subjects with KCNQ2-related encephalopathy: results from a family-driven survey","volume":"142","author":"Cossu","year":"2023","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2025.110670_b0025","unstructured":"ClinicalTrials.gov. An open-label extension of the study XEN496 (ezogabine) in children with KCNQ2-DEE (EPIK-OLE). 2023. https:\/\/clinicaltrials.gov\/study\/NCT04912856 [accessed 30 June 2025]."},{"key":"10.1016\/j.yebeh.2025.110670_b0030","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1212\/NXG.0000000000000096","article-title":"KCNQ2 encephalopathy: features, mutational hot spots, and ezogabine treatment of 11 patients","volume":"2","author":"Millichap","year":"2016","journal-title":"Neurol Genet"},{"key":"10.1016\/j.yebeh.2025.110670_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmg.2019.02.001","article-title":"Antiepileptic therapy approaches in KCNQ2 related epilepsy: a systematic review","volume":"63","author":"Kuersten","year":"2020","journal-title":"Eur J Med Genet"},{"key":"10.1016\/j.yebeh.2025.110670_b0040","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/epi.12984","article-title":"Early and effective treatment of KCNQ2 encephalopathy","volume":"56","author":"Pisano","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110670_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107854","article-title":"Why we urgently need improved seizure and epilepsy therapies for children and neonates","volume":"170","author":"Pressler","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.yebeh.2025.110670_b0050","unstructured":"Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Rare diseases: considerations for the development of drugs and biological products. Guidance for industry. 2023. https:\/\/www.fda.gov\/media\/119757\/download [accessed 30 June 2025]."},{"key":"10.1016\/j.yebeh.2025.110670_b0055","unstructured":"Maclaine G, Potashman MH, Pawar D, Sharma S, Rudell K, Lerner J, et al. Patient outcomes in KCNQ2 developmental and eppileptic encephalopathy (KNCQ2-DEE): Systematic literature review. Eur J Neurol 2024;31:189."},{"key":"10.1016\/j.yebeh.2025.110670_b0060","doi-asserted-by":"crossref","unstructured":"US Department of Health and Human Services FDA Center for Drug Evaluation and Research, US Department of Health and Human Services FDA Center for Biologics Evaluation and Research, US Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 2006;4:79. Doi: 10.1186\/1477-7525-4-79.","DOI":"10.1186\/1477-7525-4-79"},{"key":"10.1016\/j.yebeh.2025.110670_b0065","unstructured":"Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health. Patient-focused drug development: methods to identify what is important to patients. Guidance for industry, Food and Drug Administration staff, and other stakeholders. 2020. https:\/\/www.fda.gov\/media\/131230\/download [accessed 30 June 2025]."},{"key":"10.1016\/j.yebeh.2025.110670_b0070","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jval.2013.04.004","article-title":"Pediatric patient-reported outcome instruments for research to support medical product labelling: report of the ISPOR PRO good research practices for the assessment of children and adolescents task force","volume":"16","author":"Matza","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.yebeh.2025.110670_b0075","unstructured":"Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health. Patient-focused drug development: collecting comprehensive and representative input. Guidance for industry, Food and Drug Administration staff, and other stakeholders. 2020. https:\/\/www.fda.gov\/media\/139088\/download [accessed 30 June 2025]."},{"key":"10.1016\/j.yebeh.2025.110670_b0080","series-title":"Discovery of Grounded Theory: Strategies for Qualitative Research","author":"Glaser","year":"1999"},{"key":"10.1016\/j.yebeh.2025.110670_b0085","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/dmcn.15187","article-title":"Caregiver assessment of quality of life in individuals with genetic developmental and epileptic encephalopathies","volume":"64","author":"Cohen","year":"2022","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.yebeh.2025.110670_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2020.106521","article-title":"Exploring quality of life in individuals with a severe developmental and epileptic encephalopathy, CDKL5 deficiency disorder","volume":"169","author":"Leonard","year":"2021","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2025.110670_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108500","article-title":"SYNGAP1-related developmental and epileptic encephalopathy: the impact on daily life","volume":"127","author":"Lo Barco","year":"2022","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2025.110670_b0100","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s11136-018-2057-3","article-title":"Psychometric properties of the quality of life inventory-disability (QI-disability) measure","volume":"28","author":"Downs","year":"2019","journal-title":"Qual Life Res"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152550502500410X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152550502500410X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T07:36:31Z","timestamp":1780299391000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152550502500410X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":20,"alternative-id":["S152550502500410X"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2025.110670","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding lived experiences with KCNQ2 developmental and epileptic encephalopathy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2025.110670","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110670"}}